NASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Price, News & Analysis $26.32 +1.39 (+5.59%) As of 03:10 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Nurix Therapeutics Stock (NASDAQ:NRIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nurix Therapeutics alerts:Sign Up Key Stats Today's Range$24.71▼$26.2250-Day Range$22.13▼$27.7952-Week Range$10.15▼$28.23Volume2.32 million shsAverage Volume1.54 million shsMarket Capitalization$2.88 billionP/E Ratio11.36Dividend YieldN/APrice Target$34.79Consensus RatingModerate Buy Company Overview Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins. The company’s pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton’s tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation. Nurix has also advanced NX-1607, an investigational small-molecule inhibitor of CBL-B, an immune-regulatory protein intended to enhance anti-tumor immune responses. Founded in 2009, Nurix is headquartered in San Francisco, California, and conducts research and clinical development activities for potential treatments in oncology and immunology. The company’s operations and development programs are directed toward patients and markets served through global clinical trials and potential pharmaceutical partnerships. Nurix was co-founded and is led by Arthur Sands, M.D., Ph.D., who serves as chief executive officer and a member of the board of directors.AI Generated. May Contain Errors. Read More Nurix Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreNRIX MarketRank™: 3.751160015905 of 5 starsNurix Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 161st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNurix Therapeutics has a consensus price target of $34.79, representing about 34.2% upside from its current price of $25.93.Amount of Analyst CoverageNurix Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nurix Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nurix Therapeutics are expected to decrease in the coming year, from $1.15 to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is 11.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.74.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is 11.19, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.52.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 4.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.24% of the float of Nurix Therapeutics has been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 9.94.Change versus previous monthShort interest in Nurix Therapeutics has recently decreased by 1.78%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.44 News SentimentNurix Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Nurix Therapeutics this week, compared to 5 articles on an average week.Search Interest5 people have searched for NRIX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows3 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,083,206.00 in company stock.Percentage Held by Insiders6.70% of the stock of Nurix Therapeutics is held by insiders.Percentage Held by InstitutionsNurix Therapeutics has minimal institutional ownership at this time.Read more about Nurix Therapeutics' insider trading history. Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRIX Stock News HeadlinesBrokers Set Expectations for NRIX FY2027 EarningsOctober 19 at 1:28 AM | americanbankingnews.comNurix Therapeutics (NASDAQ:NRIX) Upgraded to "Buy" at Wall Street ZenOctober 17 at 1:25 AM | americanbankingnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.October 20 at 1:00 AM | Weiss Ratings (Ad)Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 1,452 Shares of StockOctober 16, 2026 | insidertrades.comNurix Therapeutics (NASDAQ:NRIX) Stock Price Up 4.1% After Analyst UpgradeOctober 16, 2026 | americanbankingnews.comNurix Therapeutics Insider Sold Shares Worth $528,528, According to a Recent SEC FilingOctober 15, 2026 | finance.yahoo.comNurix Therapeutics (NASDAQ:NRIX) Stock: Insider Julia Gregory Sells 22,583 SharesOctober 15, 2026 | insidertrades.comTruist Financial Has Lowered Expectations for Nurix Therapeutics (NASDAQ:NRIX) Stock PriceOctober 15, 2026 | americanbankingnews.comSee More Headlines NRIX Stock Analysis - Frequently Asked Questions How have NRIX shares performed this year? Nurix Therapeutics' stock was trading at $18.97 at the start of the year. Since then, NRIX shares have increased by 36.7% and is now trading at $25.93. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced its quarterly earnings results on Monday, October, 12th. The company reported $4.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.60) by $5.33. The firm had revenue of $673.06 million for the quarter, compared to analyst estimates of $24.35 million. Nurix Therapeutics had a trailing twelve-month return on equity of 49.34% and a net margin of 42.01%. When did Nurix Therapeutics IPO? Nurix Therapeutics (NRIX) raised $187 million in an initial public offering on Friday, July 24th 2020. The company issued 11,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager. Who are Nurix Therapeutics' major shareholders? Top institutional shareholders of Nurix Therapeutics include WestHill Financial Advisors Inc. (0.20%), Farther Finance Advisors LLC and GAMMA Investing LLC. Insiders that own company stock include Gwenn Hansen, Houte Hans Van, Christine Ring and Julia P Gregory. View institutional ownership trends. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA), Vertex Pharmaceuticals (VRTX), NIO (NIO) and Uber Technologies (UBER). Company Calendar Last Earnings10/12/2026Today10/20/2026Fiscal Year End11/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 NRIX's financial health is in the Green zone, according to TradeSmith. NRIX has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NRIX CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees357Year Founded2012Price Target and Rating Average Price Target for Nurix Therapeutics$34.79 High Price Target$45.00 Low Price Target$25.00 Potential Upside/Downside+32.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)$2.31 Trailing P/E Ratio11.36 Forward P/E Ratio22.89 P/E GrowthN/ANet Income-$264.46 million Net Margins42.01% Pretax Margin43.91% Return on Equity49.34% Return on Assets38.61% Debt Debt-to-Equity RatioN/A Current Ratio8.44 Quick Ratio8.44 Sales & Book Value Annual Sales$83.98 million Price / Sales34.24 Cash FlowN/A Price / Cash FlowN/A Book Value$5.29 per share Price / Book4.98Miscellaneous Outstanding Shares109,250,000Free Float101,930,000Market Cap$2.88 billion OptionableOptionable Beta1.82 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:NRIX) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle ...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredFederal Reserve’s Disturbing Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
